Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up study

This publication has 28 references indexed in Scilit:

• Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment
  Pharmacology & Therapeutics, 2006
• Phase 2 trial of sustained-release fampridine in chronic spinal cord injury
  Spinal Cord, 2006
• Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury
  Zeitschrift für Neurologie, 2001
• Absorption Characteristics of Sustained‐Release 4‐Aminopyridine (Fampridine SR) in Patients with Chronic Spinal Cord Injury
  The Journal of Clinical Pharmacology, 2000
• Safety and Efficacy of 4‐Aminopyridine in Humans with Spinal Cord Injury: A Long‐Term, Controlled Trial
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1999
• Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases.
  Spinal Cord, 1998
• Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord
  Neuroscience, 1997
• 4-Aminopyridine in Chronic Spinal Cord Injury: A Controlled, Double-Blind, Crossover Study in Eight Patients
  Journal of Neurotrauma, 1993
• 4-aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve
  Brain Research, 1985
• The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals
  European Journal of Pharmacology, 1977